Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical Limited has appointed Ms. Shelley Steyn as Chief Financial Officer, effective May 5, 2025, as part of its strategy to strengthen leadership during a critical development phase. Ms. Steyn’s extensive experience in financial roles is expected to enhance OncoSil’s strategic priorities, improve financial control, and support the company’s efforts in closing clinical trial recruitments and resubmitting a marketing authorization application to the Therapeutics Goods Association.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, specifically the OncoSil™ brachytherapy device for treating locally advanced unresectable pancreatic cancer. This device delivers targeted intratumoural placement of Phosphorous-32 in combination with chemotherapy and has received breakthrough device designation in the EU, UK, and US. The company is working towards commercializing this technology, which is approved for sale in over 30 countries.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$23.03M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.